Pelthos Therapeutics (PTHS) Shares Outstanding (2022 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Shares Outstanding (Entity) of $1.9 million for Q4 2025, up 208.09% year-over-year from $610381.0 in Q4 2024, and down 39.16% quarter-over-quarter from $3.1 million in Q3 2025.
Pelthos Therapeutics (PTHS) Shares Outstanding (2022 - 2026) Analysis & Trends
Pelthos Therapeutics' Shares Outstanding (Entity) history runs 4 years deep, the most recent figure standing at $1.9 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 208.09% year-over-year to $1.9 million; the TTM figure through Dec 2025 stood at $1.9 million (up 208.09% YoY), while the FY2025 annual figure was $1.9 million, up 208.09% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $1.9 million, down from $3.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $3.1 million in Q3 2025, with the low at $43531.0 in Q4 2022.
- The 4-year median for Shares Outstanding (Entity) is $581811.0 (2024), against an average of $691209.6.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) surged 492.44% in 2024, then rose 15.63% in 2025.
- Pelthos Therapeutics' Shares Outstanding (Entity) stood at $43531.0 in 2022, then jumped by 193.25% to $127654.0 in 2023, then soared by 378.15% to $610381.0 in 2024, then jumped by 208.09% to $1.9 million in 2025.
- Business Quant data shows PTHS's Shares Outstanding (Entity) at $1.9 million in Q4 2025, $3.1 million in Q3 2025, and $673320.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | 3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.54 Mn |
| Dec 31, 2025 | 1.88 Mn |
| Sep 30, 2025 | 3.06 Mn |
| Jun 30, 2025 | 640,518.00 |
| Mar 31, 2025 | 612,792.00 |
| Dec 31, 2024 | 557,447.00 |
| Sep 30, 2024 | 579,229.00 |
| Jun 30, 2024 | 577,371.00 |
| Mar 31, 2024 | 469,099.00 |
| Dec 31, 2023 | 127,654.00 |
| Sep 30, 2023 | 98,452.00 |
| Jun 30, 2023 | 100,278.00 |
| Mar 31, 2023 | 111,111.00 |
| Dec 31, 2022 | 43,531.00 |